AZR AE 006
Alternative Names: AZR-AE-006Latest Information Update: 21 Oct 2022
At a glance
- Originator Azura Ophthalmics
- Class Eye disorder therapies; Keratolytics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry eyes